The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy

American Journal of Pathology

Volumn 182, Issue 2, 2013, Pages 485-504

  Dorchies, Olivier M ^a   Reutenauer Patte, Julie ^a   Dahmane, Elyes ^b,c   Ismail, Hesham M ^a   Petermann, Olivier ^a   Patthey Vuadens, Ophélie ^a   Comyn, Sophie A ^a   Gayi, Elinam ^a   Piacenza, Tony ^a   Handa, Robert J ^d   Décosterd, Laurent A ^c   Ruegg, Urs T ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FORCE; LEG MUSCLE; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE THICKNESS; MUSCULOSKELETAL SYSTEM PARAMETERS; MYOFIBER COUNT; MYOFIBER DIAMETER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRICEPS BRACHII MUSCLE;

ANIMALS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; BIOMECHANICS; BODY WEIGHT; CREATINE KINASE; DIAPHRAGM; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; FIBROSIS; MICE; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; ORGAN SIZE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84872677715     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.10.018     Document Type: Article

References (94)

1. L.A. Morrison Dystrophinopathies Handb Clin Neurol 101 2011 11 39
2. N.P. Whitehead, E.W. Yeung, and D.G. Allen Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species Clin Exp Pharmacol Physiol 33 2006 657 662
3. D. Allen, O. Gervasio, E. Yeung, and N. Whitehead Calcium and the damage pathways in muscular dystrophy Can J Physiol Pharmacol 88 2010 83 91
4. C.F. Spurney Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions Muscle Nerve 44 2011 8 19
5. D.P. Judge, D.A. Kass, W.R. Thompson, and K.R. Wagner Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy Am J Cardiovasc Drugs 11 2011 287 294
6. A. Manzur, T. Kuntzer, M. Pike, and A. Swan Glucocorticoid corticosteroids for Duchenne muscular dystrophy Cochrane Database Syst Rev 1 2008 CD003725
7. R.J. Fairclough, K.J. Perkins, and K.E. Davies Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy Curr Gene Ther 12 2012 206 244
8. I.E. Verhaart, and A. Aartsma-Rus Gene therapy for Duchenne muscular dystrophy Curr Opin Neurol 25 2012 588 596
9. A.A. Larionov, D.A. Vasyliev, J.I. Mason, A.F. Howie, L.M. Berstein, and W.R. Miller Aromatase in skeletal muscle J Steroid Biochem Mol Biol 84 2003 485 492
10. A. Wiik, M. Ekman, G. Morgan, O. Johansson, E. Jansson, and M. Esbjornsson Oestrogen receptor beta is present in both muscle fibres and endothelial cells within human skeletal muscle tissue Histochem Cell Biol 124 2005 161 165
11. C. Kalbe, M. Mau, K. Wollenhaupt, and C. Rehfeldt Evidence for estrogen receptor alpha and beta expression in skeletal muscle of pigs Histochem Cell Biol 127 2006 95 107
12. R. Sarwar, B.B. Niclos, and O.M. Rutherford Changes in muscle strength, relaxation rate and fatiguability during the human menstrual cycle J Physiol (Lond) 493 Pt 1 1996 267 272
13. J.M. McClung, J.M. Davis, M.A. Wilson, E.C. Goldsmith, and J.A. Carson Estrogen status and skeletal muscle recovery from disuse atrophy J Appl Physiol 100 2006 2012 2023
14. R.W. Koot, G.J. Amelink, M.A. Blankenstein, and P.R. Bar Tamoxifen and oestrogen both protect the rat muscle against physiological damage J Steroid Biochem Mol Biol 40 1991 689 695
15. A.N. Kallen, and L. Pal Cardiovascular disease and ovarian function Curr Opin Obstet Gynecol 23 2011 258 267
16. X.-P. Yang, and J.F. Reckelhoff Estrogen, hormonal replacement therapy and cardiovascular disease Curr Opin Nephrol Hypertens 20 2011 133 138
17. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, J.N. Atkins, T.B. Bevers, L. Fehrenbacher, E.R. Pajon, J.L. Wade III, A. Robidoux, R.G. Margolese, J. James, S.M. Lippman, C.D. Runowicz, P.A. Ganz, S.E. Reis, W. McCaskill-Stevens, L.G. Ford, V.C. Jordan, N. Wolmark National Surgical Adjuvant Breast and Bowel Project (NSABP) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes JAMA 295 2006 2727 2741
18. V.G. Vogel The NSABP Study of Tamoxifen and Raloxifene (STAR) trial Expert Rev Anticancer Ther 9 2008 51 60
19. M.N. Singh, P.L. Martin-Hirsch, and F.L. Martin The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century Med Sci Monit 14 2008 RA144 RA148
20. J.B. Custodio, T.C. Dinis, L.M. Almeida, and V.M. Madeira Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity Biochem Pharmacol 47 1994 1989 1998
21. 2+ and inorganic phosphate Toxicol Appl Pharmacol 152 1998 10 17
22. M.A. Kuhn, X. Wang, W.G. Payne, F. Ko, and M.C. Robson Tamoxifen decreases fibroblast function and downregulates TGFβ2 in Dupuytren's affected palmar fascia J Surg Res 103 2002 146 152
23. W.G. Payne, F. Ko, S. Anspaugh, C.K. Wheeler, T.E. Wright, and M.C. Robson Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma Ann Plast Surg 56 2006 301 305
24. M.L. Dodds, M.E. Kargacin, and G.J. Kargacin Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum Br J Pharmacol 132 2001 1374 1382
25. 2+ uptake by estrogen receptor agonists and antagonists Br J Pharmacol 145 2005 862 871
26. K.A. Bolanz, G.G. Kovacs, C.P. Landowski, and M.A. Hediger Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells Mol Cancer Res 7 2009 2000 2010
27. W.C.J. Chung, T.R. Pak, S. Suzuki, W.A. Pouliot, M.E. Andersen, and R.J. Handa Detection and localization of an estrogen receptor beta splice variant protein (ERbeta2) in the adult female rat forebrain and midbrain regions J Comp Neurol 505 2007 249 267
28. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, and J.-A. Gustafsson Estrogen receptors: how do they signal and what are their targets Physiol Rev 87 2007 905 931
29. K. Nagaraju, and R. Willmann Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008 Neuromuscul Disord 19 2009 502 506
30. 5cv mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx mice Am J Pathol 179 2011 2464 2474
31. O.M. Dorchies, S. Wagner, O. Vuadens, K. Waldhauser, T.M. Buetler, P. Kucera, and U.T. Ruegg Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy Am J Physiol Cell Physiol 290 2006 C616 C625
32. S. Puttini, L. Lekka, O.M. Dorchies, D. Saugy, T. Incitti, U.T. Ruegg, I. Bozzoni, A.J. Kulik, and N. Mermod Gene-mediated restoration of normal myofiber elasticity in dystrophic muscles Mol Ther 17 2009 19 25
33. 5Cv mouse, a model for Duchenne muscular dystrophy J Pineal Res 51 2011 163 171
34. J. Reutenauer-Patte, F.-X. Boittin, O. Patthey-Vuadens, U.T. Ruegg, and O.M. Dorchies Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways Am J Pathol 180 2012 749 762
35. J. Reutenauer, O.M. Dorchies, O. Patthey-Vuadens, G. Vuagniaux, and U.T. Ruegg Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy Br J Pharmacol 155 2008 574 584
36. Y. Nakae, O.M. Dorchies, P.J. Stoward, B.F. Zimmermann, C. Ritter, and U.T. Ruegg Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea Histochem Cell Biol 137 2012 811 827
37. E. Dahmane, T. Mercier, B. Zanolari, S. Cruchon, N. Guignard, T. Buclin, S. Leyvraz, K. Zaman, C. Csajka, and L.A. Decosterd An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4′-hydroxylated metabolites in breast cancer patients J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 3402 3414
38. A. Briguet, I. Courdier-Fruh, M. Foster, T. Meier, and J.P. Magyar Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse Neuromuscul Disord 14 2004 675 682
39. B. Lu, E. Leygue, H. Dotzlaw, L.J. Murphy, L.C. Murphy, and P.H. Watson Estrogen receptor-β mRNA variants in human and murine tissues Mol Cell Endocrinol 138 1998 199 203
40. C.G. Carlson, J. Rutter, C. Bledsoe, R. Singh, H. Hoff, K. Bruemmer, J. Sesti, F. Gatti, J. Berge, and L. McCarthy A simple protocol for assessing inter-trial and inter-examiner reliability for two noninvasive measures of limb muscle strength J Neurosci Methods 186 2010 226 230
41. M. Furlanut, L. Franceschi, E. Pasqual, S. Bacchetti, D. Poz, G. Giorda, and P. Cagol Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women Ther Drug Monit 29 2007 349 352
42. L. Madlensky, L. Natarajan, S. Tchu, M. Pu, J. Mortimer, S.W. Flatt, D.M. Nikoloff, G. Hillman, M.R. Fontecha, H.J. Lawrence, B.A. Parker, A.H.B. Wu, and J.P. Pierce Tamoxifen metabolite concentrations. CYP2D6 genotype, and breast cancer outcomes Clin Pharmacol Ther 89 2011 718 725
43. S.P. Robinson, S.M. Langan-Fahey, D.A. Johnson, and V.C. Jordan Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient Drug Metab Dispos 19 1991 36 43
44. T.E. Murdter, W. Schroth, L. Bacchus-Gerybadze, S. Winter, G. Heinkele, W. Simon, P.A. Fasching, T. Fehm, M. Eichelbaum, M. Schwab, and H. Brauch Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma Clin Pharmacol Ther 89 2011 708 717
45. E.A. Eugster, S.D. Rubin, E.O. Reiter, P. Plourde, H.-C. Jou, and O.H. Pescovitz Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial J Pediatr 143 2003 60 66
46. C.M. Cardoso, L.M. Almeida, and J.B. Custodio 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition Mitochondrion 1 2002 485 495
47. E.F. van Bommel, T.R. Hendriksz, A.W. Huiskes, and A.G. Zeegers Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis Ann Intern Med 144 2006 101 106
48. 2+ influx via TRPV2 ameliorates muscular dystrophy in animal models Hum Mol Genet 18 2009 824 834
49. S.A. Goonasekera, C.K. Lam, D.P. Millay, M.A. Sargent, R.J. Hajjar, E.G. Kranias, and J.D. Molkentin Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle J Clin Invest 121 2011 1044 1052
50. C.F. Spurney, A. Sali, A.D. Guerron, M. Iantorno, Q. Yu, H. Gordish-Dressman, S. Rayavarapu, J. van der Meulen, E.P. Hoffman, and K. Nagaraju Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice J Cardiovasc Pharmacol Ther 16 2011 87 95
51. Y. Nakae, K. Hirasaka, J. Goto, T. Nikawa, M. Shono, M. Yoshida, and P.J. Stoward Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study Histochem Cell Biol 129 2008 489 501
52. E.A. Lien, E. Solheim, and P.M. Ueland Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment Cancer Res 51 1991 4837 4844
53. L. Gao, Y. Tu, P. Wegman, S. Wingren, and L.A. Eriksson A mechanistic hypothesis for the cytochrome P450-catalyzed cis-trans isomerization of 4-hydroxytamoxifen: an unusual redox reaction J Chem Inf Model 51 2011 2293 2301
54. K.M. McCormick, K.L. Burns, C.M. Piccone, L.E. Gosselin, and G.A. Brazeau Effects of ovariectomy and estrogen on skeletal muscle function in growing rats J Muscle Res Cell Motil 25 2004 21 27
55. C.M. Piccone, G.A. Brazeau, and K.M. McCormick Effect of oestrogen on myofibre size and myosin expression in growing rats Exp Physiol 90 2005 87 93
56. M.B. Reid Invited Review: redox modulation of skeletal muscle contraction: what we know and what we don't J Appl Physiol 90 2001 724 731
57. R.L. Hughson Regulation of blood flow at the onset of exercise by feed forward and feedback mechanisms Can J Appl Physiol 28 2003 774 787
58. B.R. Macintosh, M.E. Robillard, and E.K. Tomaras Should postactivation potentiation be the goal of your warm-up? Appl Physiol Nutr Metab 37 2012 546 550
59. A.L. Kho, S. Perera, A. Alexandrovich, and M. Gautel The sarcomeric cytoskeleton as a target for pharmacological intervention Curr Opin Pharmacol 12 2012 347 354
60. J. Mallinson, J. Meissner, and K.-C. Chang Calcineurin signaling and the slow oxidative skeletal muscle fiber type. ch 2 W.J. Kwang, International Review of Cell and Molecular Biology 2009 Academic Press 67 101
61. L.Q. Jiang, P.M. Garcia-Roves, T. de Castro Barbosa, and J.R. Zierath Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity Am J Physiol Endocrinol Metab 298 2010 E8 E16
62. K. Sakuma, and A. Yamaguchi The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle J Biomed Biotechnol 2010 2010 721219
63. N. Stupka, D.R. Plant, J.D. Schertzer, T.M. Emerson, R. Bassel-Duby, E.N. Olson, and G.S. Lynch Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice J Physiol 575 2006 645 656
64. C. Webster, L. Silberstein, A.P. Hays, and H.M. Blau Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy Cell 52 1988 503 513
65. P. Moens, P.H. Baatsen, and G. Marechal Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch J Muscle Res Cell Motil 14 1993 446 451
66. J.V. Chakkalakal, M.A. Stocksley, M.A. Harrison, L.M. Angus, J. Deschenes-Furry, S. St-Pierre, L.A. Megeney, E.R. Chin, R.N. Michel, and B.J. Jasmin Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling Proc Natl Acad Sci U S A 100 2003 7791 7796
67. J. Muller, N. Vayssiere, M. Royuela, M.E. Leger, A. Muller, F. Bacou, F. Pons, G. Hugon, and D. Mornet Comparative evolution of muscular dystrophy in diaphragm, gastrocnemius and masseter muscles from old male mdx mice J Muscle Res Cell Motil 22 2001 133 139
68. M.W. Berchtold, H. Brinkmeier, and M. Muntener Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease Physiol Rev 80 2000 1215 1265
69. C. Reggiani, and T. Kronnie RyR isoforms and fibre type-specific expression of proteins controlling intracellular calcium concentration in skeletal muscles J Muscle Res Cell Motil 27 2006 327 335
70. A. Divet, A.V. Lompré, and C. Huchet-Cadiou Effect of cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca-ATPase, on skeletal muscles from normal and mdx mice Acta Physiol Scand 184 2005 173 186
71. K. Perkins, and K. Davies The role of utrophin in the potential therapy of Duchenne muscular dystrophy Neuromuscul Disord 12 2002 S78 S89
72. D.J. Burkin, G.Q. Wallace, D.J. Milner, E.J. Chaney, J.A. Mulligan, and S.J. Kaufman Transgenic expression of α7β1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice Am J Pathol 166 2005 253 263
73. N.T. Larkins, R.M. Murphy, and G.D. Lamb Absolute amounts and diffusibility of HSP72. HSP25, and αB-crystallin in fast- and slow-twitch skeletal muscle fibers of rat Am J Physiol Cell Physiol 302 2012 C228 C239
74. A. Sanbe Molecular mechanisms of alpha-crystallinopathy and its therapeutic strategy Biol Pharm Bull 34 2011 1653 1658
75. O. Friedrich, M. Both, C. Weber, S. Schürmann, M.D.H. Teichmann, F. von Wegner, R.H.A. Fink, M. Vogel, J.S. Chamberlain, and C. Garbe Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle Biophys J 98 2010 606 616
76. B. Blaauw, L. Agatea, L. Toniolo, M. Canato, M. Quarta, K.A. Dyar, D. Danieli-Betto, R. Betto, S. Schiaffino, and C. Reggiani Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy J Appl Physiol 108 2010 105 111
77. 2+ homeostasis during fatigue Exp Physiol 95 2010 641 656
78. T. Saartok Steroid receptors in two types of rabbit skeletal muscle Int J Sports Med 5 1984 130 136
79. D. Feder, I.R.B. Godoy, M.L.G. Pereira, C.S. Silva, D.N. Silvestre, F.L.A. Fonseca, A.A.S. Carvalho, R.A. Santos, and M.H.C. Carvalho Hormonal receptors in skeletal muscles of dystrophic mice J Biomed Biotechnol 2012 (in press)
80. D. Chau, J.S. Mancoll, S. Lee, J. Zhao, L.G. Phillips, G.K. Gittes, and M.T. Longaker Tamoxifen downregulates TGF-beta production in keloid fibroblasts Ann Plast Surg 40 1998 490 493
81. H.H. Stedman, H.L. Sweeney, J.B. Shrager, H.C. Maguire, R.A. Panettieri, B. Petrof, M. Narusawa, J.M. Leferovich, J.T. Sladky, and A.M. Kelly The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy Nature 352 1991 536 539
82. L.E. Gosselin, and K.M. McCormick Targeting the immune system to improve ventilatory function in muscular dystrophy Med Sci Sports Exerc 36 2004 44 51
83. A.P.T. Taniguti, A. Pertille, C.Y. Matsumura, H.S. Neto, and M.J. Marques Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker Muscle Nerve 43 2011 82 87
84. J.B. Custodio, L.M. Almeida, and V.M. Madeira The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes Biochim Biophys Acta 1150 1993 123 129
85. A. Pedram, M. Razandi, D. Lubahn, J. Liu, M. Vannan, and E.R. Levin Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-β to inhibit calcineurin Endocrinology 149 2008 3361 3369
86. A. Pedram, M. Razandi, F. O'Mahony, D. Lubahn, and E.R. Levin Estrogen receptor-β prevents cardiac fibrosis Mol Endocrinol 24 2010 2152 2165
87. C.J. Gruber, D.M. Gruber, I.M.L. Gruber, F. Wieser, and J.C. Huber Anatomy of the estrogen response element Trends Endocrinol Metab 15 2004 73 78
88. J.J. Zhang, T.J. Jacob, M.A. Valverde, S.P. Hardy, G.M. Mintenig, F.V. Sepulveda, D.R. Gill, S.C. Hyde, A.E. Trezise, and C.F. Higgins Tamoxifen blocks chloride channels. A possible mechanism for cataract formation J Clin Invest 94 1994 1690 1697
89. M.P. Goetz, A. Kamal, and M.M. Ames Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response Clin Pharmacol Ther 83 2007 160 166
90. T.G. Hayes Pharmacologic treatment of male breast cancer Expert Opin Pharmacother 10 2009 2499 2510
91. O. Derman, N. Kanbur, I. Kilic, and T. Kutluk Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia J Pediatr Endocrinol Metab 21 2008 449 454
92. N.C. Kreher, E.A. Eugster, and R.R. Shankar The use of tamoxifen to improve height potential in short pubertal boys Pediatrics 116 2005 1513 1515
93. M.L. Bianchi, D. Biggar, K. Bushby, A.D. Rogol, M.M. Rutter, and B. Tseng Endocrine aspects of Duchenne muscular dystrophy Neuromuscul Disord 21 2011 298 303
94. L.M. Starnes, C.M. Downey, S.K. Boyd, and F.R. Jirik Increased bone mass in male and female mice following tamoxifen administration Genesis 45 2007 229 235